XWELL Inc. (XWEL)
Official siteHEALTHCARE • DIAGNOSTICS & RESEARCH • NASDAQ
Market Cap: $5.62M
Last updated: Nov 17, 2026 at 11:02 AM ET
XWELL Inc. (XWEL) Earnings: Report Dates and Results
XWELL (XWEL) is expected to report earnings on Mar 30, 2027. In the quarter ended Jun 30, 2026, XWELL reported EPS of -$0.26. It beat the EPS estimate in 6 of the 8 most recent quarters that had an estimate.
Earnings
Performance (10Y)
Next Report
XWEL has an expected report date of Mar 30, 2027.
XWEL Earnings Call
The latest XWEL earnings call transcript on file is labeled 2024Q3.
Read the 2024Q3 transcriptEarnings History
Of the 23 quarters below that had an estimate, XWEL beat 10 and missed 13. Revenue for the quarter ended Jun 30, 2026 was $7.14M, down 7.2% from $7.69M a year earlier.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Jun 30, 2026 | -$0.26 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Aug 14, 2026 | $7.14M |
| Mar 31, 2026 | -$1.51 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Apr 21, 2026 | $6.64M |
| Sep 30, 2025 | -$0.26 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Nov 14, 2025 | $7.34M |
| Jun 30, 2025 | -$0.56 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Aug 14, 2025 | $7.69M |
| Mar 31, 2025 | -$1.44 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | May 20, 2025 | $7.02M |
| Sep 30, 2024 | -$0.99 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Nov 14, 2024 | $8.42M |
| Jun 30, 2024 | -$0.48 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Aug 14, 2024 | $9.28M |
| Mar 31, 2024 | -$1.57 | N/A | N/A | N/A | N/A | N/A | N/A | 0 up, 0 down | Apr 16, 2024 | $8.73M |
| Sep 30, 2023 | -$0.77 | -$0.80 | -$0.80 - -$0.80 | +3.75% | Beat | N/A | 1 | 0 up, 0 down | Nov 14, 2023 | $7.47M |
| Jun 30, 2023 | -$1.37 | -$1.40 | -$1.40 - -$1.40 | +2.14% | Beat | N/A | 1 | 0 up, 0 down | Aug 14, 2023 | $8.18M |
| Mar 31, 2023 | -$1.30 | -$2.60 | -$2.60 - -$2.60 | +50.00% | Beat | N/A | 1 | 0 up, 0 down | Apr 17, 2023 | $7.06M |
| Dec 31, 2022 | -$0.08 | -$0.05 | N/A | -60.00% | Miss | -366.7% | 1 | 0 up, 0 down | Mar 21, 2023 | $7.56M |
| Sep 30, 2022 | -$1.30 | -$1.40 | -$1.40 - -$1.40 | +7.14% | Beat | -230.0% | 1 | 0 up, 0 down | Nov 14, 2022 | $10.74M |
| Jun 30, 2022 | -$1.67 | -$2.00 | N/A | +16.50% | Beat | N/A | N/A | N/A | Aug 15, 2022 | $13.60M |
| Mar 31, 2022 | -$0.80 | -$1.20 | N/A | +33.33% | Beat | N/A | N/A | N/A | May 16, 2022 | $24.05M |
| Dec 31, 2021 | $0.03 | $0.06 | N/A | -50.00% | Miss | N/A | N/A | N/A | Mar 15, 2022 | $29.36M |
| Sep 30, 2021 | $1.00 | -$0.80 | N/A | +225.00% | Beat | N/A | N/A | N/A | Nov 15, 2021 | $26.77M |
| Jun 30, 2021 | -$0.80 | -$0.60 | N/A | -33.33% | Miss | N/A | N/A | N/A | Aug 16, 2021 | $9.09M |
| Mar 31, 2021 | -$0.20 | -$1.00 | N/A | +80.00% | Beat | N/A | N/A | N/A | May 17, 2021 | $8.51M |
| Dec 31, 2020 | -$0.22 | -$0.07 | N/A | -214.29% | Miss | N/A | N/A | N/A | Mar 31, 2021 | $185000 |
| Sep 30, 2020 | -$0.10 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Nov 16, 2020 | $339000 |
| Jun 30, 2020 | -$1.49 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Aug 19, 2020 | $143000 |
| Mar 31, 2020 | -$5.07 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Apr 20, 2020 | $7.72M |
| Dec 31, 2019 | -$0.55 | -$0.47 | N/A | -17.87% | Miss | N/A | N/A | N/A | Mar 31, 2020 | N/A |
| Sep 30, 2019 | -$5.04 | -$4.20 | N/A | -19.99% | Miss | N/A | N/A | N/A | Nov 14, 2019 | $12.53M |
| Jun 30, 2019 | -$9.66 | -$1.40 | N/A | -590.00% | Miss | N/A | N/A | N/A | Aug 14, 2019 | $25.82M |
| Mar 31, 2019 | -$4.83 | -$6.00 | N/A | +19.51% | Beat | N/A | N/A | N/A | May 15, 2019 | $12.23M |
| Dec 31, 2018 | -$52.77 | -$44.00 | N/A | -19.93% | Miss | N/A | N/A | N/A | Mar 28, 2019 | $11.53M |
| Sep 30, 2018 | -$116.16 | -$144.00 | N/A | +19.33% | Beat | N/A | N/A | N/A | Nov 14, 2018 | $12.92M |
| Jun 30, 2018 | -$108.12 | -$84.00 | N/A | -28.71% | Miss | N/A | N/A | N/A | Aug 14, 2018 | $13.04M |
| Mar 31, 2018 | -$170.04 | -$96.00 | N/A | -77.13% | Miss | N/A | N/A | N/A | May 15, 2018 | $12.60M |
| Dec 31, 2017 | -$25.20 | -$6.00 | N/A | -320.00% | Miss | N/A | N/A | N/A | Mar 29, 2018 | $11.96M |
| Sep 30, 2017 | -$228.00 | -$132.00 | N/A | -72.73% | Miss | N/A | N/A | N/A | Nov 9, 2017 | $12.85M |
| Jun 30, 2017 | -$336.00 | -$156.00 | N/A | -115.38% | Miss | N/A | N/A | N/A | Aug 9, 2017 | $12.93M |
| Mar 31, 2017 | -$20.40 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | May 15, 2017 | $11.08M |
| Dec 31, 2016 | -$13.80 | N/A | N/A | N/A | N/A | -118.8% | N/A | N/A | Mar 30, 2017 | N/A |
| Sep 30, 2016 | -$20.40 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Nov 9, 2016 | $3.10M |
| Jun 30, 2016 | -$43.25 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Aug 8, 2016 | $11.35M |
| Mar 31, 2016 | -$16.76 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | May 5, 2016 | $2.04M |
| Dec 31, 2015 | $73.52 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Mar 10, 2016 | $22.54M |
Estimates made before a stock split are shown on the same share basis as the reported EPS.
Annual EPS
EPS for the fiscal year ended Dec 31, 2022 was -$3.85, after $0.03 the year before. It was -$6,127.20 for the year ended Dec 31, 2013, the oldest of the 10 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2022 | -$3.85 | -12933.3% |
| Dec 31, 2021 | $0.03 | N/A |
| Dec 31, 2020 | -$6.88 | N/A |
| Dec 31, 2019 | -$20.08 | N/A |
| Dec 31, 2018 | -$447.09 | N/A |
| Dec 31, 2017 | -$609.60 | N/A |
| Dec 31, 2016 | -$94.21 | N/A |
| Dec 31, 2015 | -$94.72 | N/A |
| Dec 31, 2014 | -$734.34 | N/A |
| Dec 31, 2013 | -$6,127.20 | N/A |
Earnings Calls
The only earnings call listed below, 2024Q3 for the period ended Sep 30, 2024, runs about 1,700 words across 3 speakers.
| Call | Period ending | Words | Speakers | Transcript |
|---|---|---|---|---|
| 2024Q3 | Sep 30, 2024 | 1,693 | 3 |
2024Q3 Earnings Call
Opening remarks
Suzanne Scrabis CFO Good day, everyone. Welcome to XWELL’s conference call to review our third quarter 2024 financial results. Joining me on today’s call is Ezra Ernst, XWELL’s Chief Executive Officer. We have posted our fiscal year earnings release on the Investor Relations section of our website located at www.xwell.com. A link to the webcast of today’s conference call can also be found on our site. Before turning the call over to Ezra for his prepared remarks, we need to advise you of the following. Comments made on today’s call may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements are based on current assumptions as of the date of this earnings conference call and webcast and opinions that involve a variety of known and unknown risks and uncertainties. Actual results may differ materially from those contained in or suggested by such forward-looking statements. Important factors that might cause such differences include those set forth from time to time in our SEC filings, including our annual report on Form 10-K for the year ended December 31, 2023, as well as our other current and periodic reports that we file with the SEC. With that said, I’d now like to turn the call over to Ezra.
Ezra Ernst CEO Thank you so much, Suzanne. I want to thank everyone who’s joining us on the call today and also express our appreciation for your continued interest in XWELL. As this is my first earnings call as the company’s CEO, I’d like to give you a brief overview of my 25-plus year career. For those of you who may not know me, I’ve been with XWELL for several years, having first served as CEO of our HyperPointe brand beginning in March of 2020 and CEO of XpresCheck brand since January of 2022. Operationally, during this time, I led the collaboration with the Center for Disease Control and Prevention under which we helped establish the CDC’s Traveler-based Genomic Surveillance program. Initially, it was a small pilot. It was built on XpresCheck’s advanced COVID-19 testing capabilities and HyperPointe’s marketing expertise. Over time we evolved the program into a key component of the United States’ biosecurity infrastructure, and we continue to be very proud of the important work we are doing with our partners and the CDC. Prior to joining XWELL, I held multiple senior management positions, including CEO of Physician’s Weekly, Chief Commercial Officer of Treato, General Manager at WebMD, and President at OptumHealth Education, a UnitedHealthcare company, as well as a few others.
Frequently Asked Questions About XWEL
When is XWELL's next earnings date?
XWELL's next earnings report is expected for Mar 30, 2027.
How often does XWEL beat earnings estimates?
XWELL beat the EPS estimate in 6 of the 8 most recent quarters that had an estimate, with an average surprise of +0.36%.
XWEL pages: Overview, Earnings, Financials, Valuation, Competitors, Government Contracts